CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

Despite the heterogeneity of acute myeloid leukemia (AML), overexpression of the interleukin-3 receptor-α (CD123) on both the more differentiated leukemic blast and leukemic stem cells (LSCs) provides a therapeutic target for antibody treatment. Here we present data on the potential clinical activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, L H, Biondo, M, Busfield, S J, Arruda, A, Yang, X, Vairo, G, Minden, M D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520399/
https://www.ncbi.nlm.nih.gov/pubmed/28574487
http://dx.doi.org/10.1038/bcj.2017.52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520399/
https://www.ncbi.nlm.nih.gov/pubmed/28574487
http://dx.doi.org/10.1038/bcj.2017.52

Ejemplares similares